The market approval of Kymriah by Novartis, a commercially available CAR-T (chimeric antigen receptor-T cell) treatment in the domestic market, is imminent.

Kymriah is the first CAR-T treatment approved by the US FDA, and it applied for approval in Korea earlier last year.

According to the industry on the 1st, Kymriah recently completed the safety and efficacy review by the MFDS, and is about to get item approval.

It can be said that a new drug is almost finished after the safety and efficacy review is normally completed. Moreover, Kymriah applied for approval in Korea early last year, and it is a drug that has been reviewed for a long time.

By the US FDA, K